916-P: SGLT2 Inhibitors and Parkinson’s Disease (PD) Risk in Older Populations with Type 2 Diabetes (T2D)

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes2024 · 8 citations
2. 2920-P: Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Dementia and Parkinson’s disease among Patients with Type 2 Diabetes—A Longitudinal, Nationwide, Population-Based Cohort Study2024
3. 3Do SGLT2 Inhibitors Influence Parkinson’s Disease Risk? A Meta-analysis of Randomized Trials (P6-17.012)2026
4. 4Association Between SGLT2 Inhibitors and Risk of Dementia and Parkinson's Disease: A Meta-Analysis of 12 Randomized Controlled Trials2024 · 26 citations
5. 5750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes2024